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Autoimmune hepatitis (AIH) is a chronic liver disease of unknown aetiology characterized by circulating autoantibodies,
hyperglobulinaemia and interface hepatitis. The mechanisms of progression from initial autoimmune attack to fibrosis and cirrhosis are
unclear but oxidant stress may be involved. Markers of lipid peroxidation, antioxidant status, hepatic fibrogenesis and liver function were
measured in blood and urine in 35 controls and in 33 patients with type-1 AIH; histology was assessed in 18 patients. In AIH, markers of
lipid peroxidation were significantly elevated (8-isoprostane in both plasma and urine P< 0.001; plasma malondialdehyde P= 0.017). Total
antioxidant capacity in protein-free serum and total glutathione in both whole blood and plasma were significantly reduced (P= 0.007,
P= 0.037, P< 0.001, respectively). The antioxidants selenium, vitamin A and vitamin E were significantly decreased (P= 0.007, P < 0.001,
P= 0.025, respectively); vitamin C was unchanged. Urinary 8-isoprostane correlated positively with interface hepatitis and nec-
roinflammatory score and with hepatic fibrogenesis (type III procollagen peptide). Interface hepatitis correlated negatively with vitamin A
and whole blood total glutathione. Oxidant stress, as reflected in blood and urine by a wide range of pro- and antioxidant markers, is a
significant feature of AIH and provides a probable mechanism linking hepatic necroinflammation to fibrogenesis and disease progression.
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1. Introduction tological activity [2]. AIH is diagnosed after exclusion ofAutoimmune hepatitis (AIH) can be defined as ‘‘an
unresolving, predominantly periportal hepatitis, usually with
hypergammaglobulinaemia and tissue autoantibodies, which
is responsive to immunosuppressive therapy in most cases’’
[1]. It typically fluctuates clinically and biochemically, and
can apparently resolve temporarily despite continuing his-0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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Histology characteristically reveals portal and periportal
lympho-plasmacytic infiltration with disruption of the lim-
iting plate. ‘‘Piecemeal necrosis’’ of periportal hepatocytes
is the hallmark of the moderate and severe forms of AIH [3]
and, recently, a histological grading system (degree of
inflammatory activity) and staging (extent of fibrosis) has
been introduced [4]. Regardless of aetiological agent, the
most important factor determining disease activity is the
extent of inflammatory activity at the portal tract/hepatic
parenchyma interface; this ‘‘piecemeal necrosis’’ is now
more accurately described as interface hepatitis, being an
example of apoptosis rather than necrosis [5]. Interface
hepatitis is a major component of the diagnostic scoring
system introduced by the International Autoimmune Hepa-
titis Group [6,7].
Subclassifications of AIH are made on the basis of the
autoantibody profile present [2,6,8]. Type 1, 70–80% of
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muscle antibodies (SMA) or both; type 2, 3–4% of AIH,
is positive for liver-kidney-microsomal antibodies (anti-
LKM1) reacting with a cytochrome isoenzyme P450 2D6;
most of the remaining 10–20% of AIH patients are positive
for soluble liver antigen (SLA) or a liver-pancreas (LP)
antigen and are classified as type 3. SLA and LP have
recently been shown to be identical (anti-SLA/LP [9]). None
of the major autoantigens detected in AIH is liver-specific,
and only very few are disease specific [8] and therefore
cannot be used diagnostically.
The autoimmune response may arise in genetically pre-
disposed individuals subsequent to a ‘‘triggering’’ environ-
mental agent, such as the drug monocycline [10] or the
HCV virus [11]. Although most AIH (87%) responds to
immunomodulatory therapy, only 15% of individuals have
complete resolution for at least 5 years; 40% progress to
cirrhosis after 10 years [12]. Since the pathophysiological
basis underlying progression from inflammation to fibrosis
is incompletely understood, we have investigated the pos-
sible role of oxidative stress in progression of AIH.
Oxidant stress has been observed in chronic viral hepa-
titis [13,14], primary biliary cirrhosis [15,16] and alcoholic
liver disease [17]. Reactive oxygen species generated during
inflammation and lipid peroxidation products, such as
malondialdehyde (MDA) or 4-hydroxynonenal (HNE) (or
their adducts), can directly activate hepatic stellate cells to
myofibroblasts [18,19] leading to fibrosis and cirrhosis. The
inflammatory and pro-fibrogenic cytokine TGFh, released
by Kupffer cells and other liver macrophages as a result of
redox-sensitive reactions, may also play a key role [20].
This study examines oxidant stress in type I AIH by
measuring, in blood and urine, a wide range of markers
reflecting both pro- and antioxidant facets of the process.
Although oxidant stress is now a recognized feature of
decompensated cirrhosis, we wished to determine wheth-
er oxidant stress is also a feature of early disease and
may therefore be implicated in the progression to fibrosis
and cirrhosis, suggesting a potential therapeutic role for
antioxidants.2. Materials and methods
2.1. Study groups
The study was approved by the Central Manchester
Health Authority Research Ethics Committee and all
patients gave written informed consent. All subjects were
nonsmokers, took no vitamin supplements and had a normal
nutritional status. All AIH patients fulfilled conventional
diagnostic criteria (raised serum IgG levels; presence of
circulating antibodies to nuclei and/or smooth muscle) and a
liver biopsy compatible with this diagnosis. Patients were
also classified using the International AIH Group scoring
system [7] for the diagnosis of AIH; ‘‘definite’’ score:pretreatment >15, posttreatment >17. ‘‘probable’’ score:
pretreatment 10–15, posttreatment 12–17. Of the 33
patients, 20 had ‘‘definite’’ AIH and 13 had ‘‘probable’’
AIH. Thirteen patients were untreated (11 naı¨ve, 2 off
treatment for at least 3 years); the remainder were currently
receiving prednisolone (2–40 mg daily) and/or azathioprine
(50–100 mg daily). As the AIH patients were predominant-
ly older females, care was taken to ensure that patient and
control groups were age- and sex-matched (control group
n = 35, 7h 28U, age = 52.2F 12.9 years, range 21–79 years:
AIH group n= 33, 5h 28U, age = 46.5F 17.2 years, range
15–79 years).
2.2. Liver biopsy
A subset of AIH patients (n = 18) had undergone liver
biopsy within 10 months of entry to this study (mean
time = 70 days). Needle biopsies were assessed by the
standard Ishak scoring method [4] for necroinflammation
and fibrosis by an experienced hepatopathologist. The total
necroinflammatory score is the sum of the scores for A—
interface hepatitis; B—bridging necrosis; C—lobular in-
flammation; and D—portal inflammation.
2.3. Specimen processing
Blood and urine samples were collected after overnight
fasting. For measurement of MDA and 8-isoprostane, blood
was collected into ice-cold tubes containing EDTA (1 mg/
ml) and GSH (1 mg/ml) and, after centrifugation (800 g,
10 min), the plasma was protected from oxidation during
storage by addition of the chain-breaking antioxidant butyl-
ated hydroxytoluene (200 Ag/ml). Urine was protected by
addition of indomethacin (0.001% w/v) to prevent in vitro
formation of prostanoids due to any leucocyte contamina-
tion [21]. Whole blood for glutathione assay was kept on ice
and analysed on the morning of collection. All other
samples were stored at  70jC prior to assay.
2.4. Analytical procedures
A more detailed description of the assays employed can
be found in a previous publication [16].
Lipid peroxidation markers: Plasma and urine samples
were assayed [21] for 8-iso-PGF2a.using an enzyme-linked
immunoassay kit (Cayman Chemicals, Ann Arbor, MI),
urinary creatinine being estimated with alkaline picrate
solution [22]. MDA was determined in acid-precipitated
serum as TBARS [23] or, most sensitively, in whole serum
as DETBARS [24].
Antioxidant markers: Total antioxidant capacity was
measured in whole and protein-free serum by an enhanced
chemiluminescent technique [25]. Selenium was determined
using a simple single-tube fluorimetric assay [26]. Vitamin
A [27], vitamin C [28] and vitamin E [29] were determined
by established laboratory techniques. Total glutathione in
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determined using 5,5V-dithio-bis(2-nitrobenzoic acid) [30].
Other markers: Hepatic fibrogenic activity was measured
in serum using the Type III procollagen intact PIIINP
radioimmunoassay (Orion Diagnostica, Espoo, Finland).
Serum AST, ALT, ALP, gGT, total protein, albumin, biliru-
bin and urate were determined by standard automated
techniques.
Statistics: Since much of the data was not normally
distributed, all values are expressed as medians with
interquartile ranges; non-parametric statistics were em-
ployed. Differences between groups were assessed using
the Mann–Whitney U-test. The significance of correla-
tions between parameters was assessed using the Spear-
man rank test.3. Results
The concentrations, in AIH and control groups, of all
markers determined in this study are shown in Table 1.
There is clear evidence of oxidative stress in the group of
all AIH patients in that 8-isoprostane was significantly
elevated (P < 0.001) in both urine and plasma. Although
MDA by TBARS was not raised, when MDA was
measured by the more sensitive DETBARS method,Table 1
Oxidant stress in control and AIH groups: markers of lipid peroxidation, antiox
parameters
Assay Control AIH, all
8-Isoprostane (u) 0.31 (0.21–0.45) 1.12a (0.78–
8-Isoprostane (p) 15.71 (11.43–19.22) 84.68a (61.41–
MDA (TBARS) 2.05 (1.77–2.90) 2.06 (1.44–
MDA (DETBARS) 2.50 (2.17–2.96) 2.86a (2.34–
Total antioxidant (ws) 0.96 (0.78–1.30) 0.82 (0.67–
Total antioxidant (pfs) 0.45 (0.37–0.50) 0.35a (0.28–
Total glutathione (wb) 1.42 (1.31–1.70) 1.38a (1.08–
Total glutathione (p) 2.67 (1.92–3.11) 1.56a (1.22–
GSSG/(GSH+GSSG) 9.6 (7.5–10.4) 9.7 (6.2–
Selenium 98.97 (91.84–105.2) 93.27a (73.02–
Vitamin A 3.59 (3.10–4.58) 2.75a (1.83–
Vitamin C 17.67 (13.15–21.44) 16.56 (11.61–
Vitamin E 14.28 (12.65–16.32) 11.90a (9.90–
PIIINP 2.95 (2.40–3.30) 4.65a (3.20–
AST 21 (19–24) 40a (31–
ALT 17 (15–22) 44a (20–
ALP 169 (144–197) 214a (160–
gGT 16 (12–22) 73a (37–
Total protein 78 (76–80) 80 (75–
Albumin 46 (45–48) 42a (38–
Bilirubin 10 (9–15) 15a (10–
Urate 0.26 (0.20–0.30) 0.22 (0.18–
Values shown as medians with interquartile ranges. P values (< 0.05) derived by th
expressed as follows: urinary 8-isoprostane as ng/g creatinine; plasma 8-isoprostan
and bilirubin as Amol/l; total glutathione (wb) as mM; total antioxidant (ws and p
PIIINP as Ag/l; vitamins C and E as mg/l; total protein and albumin as g/l; AST, A
serum, pfs = protein-free serum, wb=whole blood.AIH patients showed a significant elevation (P= 0.017).
Urinary 8-isoprostane and plasma MDA (by DETBARS)
were the two lipid peroxidation marker assays of choice
(Fig. 1a and b). Antioxidant status was compromised in
AIH patients, with several important components of the
antioxidant defence mechanism being significantly de-
creased. Although the total antioxidant capacity in whole
serum was reduced in AIH patients, the decrease was not
significant. However, the total antioxidant capacity in
protein-free serum did show a significant reduction (P=
0.007) (Fig. 1c), suggesting that protein-free components
make an important contribution. Total glutathione (GSH
+ GSSG) in whole blood, a measure of intracellular
antioxidant reserve, showed a small, but significant,
reduction (P= 0.037). A more striking antioxidant deple-
tion occurred with total glutathione in plasma, where
levels were significantly reduced (P < 0.001) to about
58% of control values (Fig. 1d). Plasma GSSG, ex-
pressed as a percentage of total plasma glutathione, was
unchanged in AIH patients. Individual antioxidants were
also shown to be affected; serum levels of selenium (Fig.
1e), vitamin A (Fig. 1f) and vitamin E were significantly
diminished (P= 0.007, P < 0.001, P= 0.025, respectively).
In contrast, vitamin C and urate were unchanged. Serum
PIIINP was significantly elevated (P < 0.001) in AIH
patients, demonstrating that hepatic fibrogenesis is aidant status, hepatic fibrogenesis, hepatic function and other biochemical
AIH, untreated AIH, treated
2.13) 1.37a (0.79–4.07) 1.11a (0.78–1.34)
127.6) 93.75a (71.82–174.9) 82.65a (58.72–106.4)
2.64) 2.79 (1.99–5.93) 1.83 (1.29–2.32)
5.35) 5.40a (2.51–13.76) 2.76 (2.34–3.75)
1.10) 1.10 (0.73–1.18) 0.79a b (0.65–0.89)
0.45) 0.39 (0.28–0.51) 0.35a (0.28–0.42)
1.43) 1.37a (0.76–1.41) 1.42 (1.16–1.44)
1.93) 1.58a (0.86–2.08) 1.53a (1.29–1.84)
14.3) 14.9 (6.9–21.1) 9.3 (5.0–12.7)
98.01) 93.41 (74.01–101.2) 91.18a (73.96–98.01)
3.18) 2.11a (1.30–2.97) 2.90a (2.36–3.31)
18.57) 17.01 (9.48–19.31) 16.56 (13.08–18.55)
14.99) 10.52 (8.95–15.62) 12.77 (10.26–14.43)
8.20) 10.00a (4.75–19.80) 3.50a b (3.05–5.25)
172) 158a (31–818) 37a (30–64)
117) 61a (20–402) 35a (22–86)
323) 289a (211–486) 199b (152–244)
118) 73a (49–115) 73a (30–118)
83) 80 (72–83) 79 (75–85)
46) 39a (32–45) 43a (40–46)
71) 66a (10–244) 15a (11–30)
0.30) 0.19 (0.13–0.31) 0.22 (0.21–0.28)
e Mann–Whitney test (a vs. control group; b vs. AIH untreated). Units were
e as ng/l; MDA (TBARS and DETBARS), total glutathione (p), vitamin A
fs) as Amol/l trolox equivalents; GSSG/(GSH+GSSG) as %; selenium and
LT, ALP and gGT as U/l; urate as mmol/l. u = urine, p = plasma, ws =whole
Fig. 1. Key markers of lipid peroxidation and antioxidant status in control and AIH groups. Medians are indicated. P values derived by the Mann–Whitney
test.
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enzyme markers of hepatic injury (AST, ALT, ALP and
gGT) were also significantly raised (P < 0.001) in the
AIH group. Albumin was reduced significantly
( P < 0.001) in the AIH group whilst total protein
remained unchanged. Although serum bilirubin was sig-
nificantly higher (P= 0.005) in the AIH group than in
the controls, almost all values were within the normal
range.
There is some evidence for a reduction of oxidant stress
in treated AIH patients (Table 1) as MDA levels (by
DETBARS) and total glutathione (whole blood) in the
treated group are no different from control levels. PIIINP,
total antioxidant (whole serum) and ALP levels were
significantly reduced (P= 0.008, P= 0.041, P= 0.028, re-
spectively) in the treated group compared with the untreated
group.
In the combined group of AIH patients, urinary 8-
isoprostane correlated positively with total necroinflamma-
tory score r = 0.54, P= 0.024, but more strongly with
interface hepatitis r= 0.69, P= 0.002 (Fig. 2a). Urinary 8-isoprostane also correlated positively with hepatic fibro-
genesis (PIIINP: r= 0.53, P= 0.002) and with markers of
hepatic injury (AST: r = 0.70, P < 0.001; ALT: r = 0.58,
P < 0.001; ALP: r = 0.54, P= 0.002; bilirubin: r = 0.53,
P= 0.002; a˜GT: r = 0.40, P= 0.040). Urinary 8-isoprostane
correlated negatively with antioxidant markers (vitamin A:
r = 0.49, P= 0.009; vitamin E: r = 0.49, P= 0.008; plas-
ma total glutathione: r = 0.46, P= 0.027). Other markers
of lipid peroxidation (MDA by TBARS: r = 0.85, P < 0.001;
MDA by DETBARS: r = 0.89, P < 0.001, Fig. 2b) also
correlated strongly with interface hepatitis. Interface hepa-
titis also correlated with hepatic fibrogenesis (PIIINP:
r = 0.79, P < 0.001 Fig. 2c) and with hepatic injury (ALT:
r = 0.74, P < 0.001; AST: r = 0.77, P= 0.004, bilirubin:
r = 0.82, P < 0.001), and negatively with antioxidant
markers (vitamin A: r = 0.63, P= 0.012; whole blood total
glutathione: r= 0.84, P < 0.001, Fig. 2d). A similar pattern
of correlations was found with total necroinflammatory
score but with lower r values and less significant P values.
Of the 18 patients biopsied, 15 had a fibrotic score between
1 and 3, two patients had a score of 4, and only one was
Fig. 2. Correlation of urinary 8-isoprostane, MDA, PIIINP and whole blood total glutathione with interface hepatitis in AIH patients. r and P values derived by
the Spearman test.
P.W. Pemberton et al. / Biochimica et Biophysica Acta 1689 (2004) 182–189186cirrhotic (score of 6). No correlation was found between
fibrotic score and any of the markers used in this study.4. Discussion
Oxidant stress, now recognized in several forms of chro-
nic liver disease, arises from an imbalance between radical-
generating and radical-scavenging activity, thereby increas-
ing formation of oxidation products and decreasing or
depleting endogenous antioxidant protection mechanisms.
The highly reactive free radical can damage the cell by
peroxidation of phospholipid membranes and oxidation of
proteins and DNA, possibly leading to malignant transfor-
mation [31]. Paradis et al. [32] demonstrated histochemi-
cally, in a variety of liver diseases, that lipid peroxidation
by-products were present. Only one of five cases of AIH
showed intracellular cytoplasmic staining of hepatocytes
with specific anti-HNE or anti-MDA antibodies. However,
HNE adducts were associated with large bundles of collagen
fibres in the portal tracts and fibrous septa, whilst MDA
labelling displayed a thin network of fibres but did not stainthe large collagen bundles. In some cases, the staining was
more intense around bile ducts and at the periphery of portal
tracts and fibrous septa in areas of fibrogenesis, and was
probably localised in hepatic stellate cells. Liver biopsy is,
however, unsuitable for regular monitoring of response to
treatment and the histochemical techniques currently avail-
able are semi-quantitative, at best. For the routine investi-
gation of oxidant stress, the measurement of pro- and
antioxidant markers in blood and urine represents the only
currently available, noninvasive approach and complements
the limited histochemical information available.
Assessment of oxidative damage to lipids traditionally
employs the TBARS assay for MDA, a peroxidation prod-
uct of polyunsaturated fatty acids. However, as previously
demonstrated in hepatitis C [14] and confirmed in this study,
urinary 8-isoprostane, a free radical mediated product of
arachidonic acid peroxidation, is more sensitive. Plasma and
urinary 8-isoprostane levels were four- to fivefold higher in
the total AIH group than in controls. Although MDA (by
DETBARS) was also significantly increased, median levels
in AIH were only 14% higher than controls. Urine and
plasma levels of 8-isoprostane become elevated under con-
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[33] and following carbon tetrachloride-induced liver injury
in the rat [34,35].
The total antioxidant assay provides a global assessment
of aqueous and lipid phase antioxidant reserves, reflecting a
complex array of factors, such as tissue antioxidant turnover
rate, ascorbic acid and tocopherol recycling, and bilirubin
production [25]. Although no decrease in total antioxidant
capacity in whole serum was observed, a significant deple-
tion was found in protein-free serum, suggesting that the
factors involved are not protein-bound antioxidants (-SH
groups on proteins, vitamin E residing on the lipoprotein
moiety and bilirubin bound to albumin).
The antioxidant defence system includes a wide range of
enzymatic and nonenzymatic components [36] several of
which were reduced in this study. Selenium is an essential
cofactor of glutathione peroxidase, the enzyme responsible
for catalysing hydroperoxide reduction by glutathione. In
our patients, serum selenium showed a small but significant
reduction. Selenium levels have been shown to be low in
liver disease generally, irrespective of aetiology, suggesting
a relationship to overall nutritional status rather than dietary
intake [37]. Burk et al. [38] showed that plasma selenium in
a variety of liver diseases declined in proportion to the
severity of the cirrhotic condition as indicated by the Child’s
grade.
Total plasma glutathione mainly reflects the intrahepatic
concentration and the balance between efflux from the liver
and uptake by the kidney [39]. In our AIH group, both
whole blood and plasma glutathione were reduced, suggest-
ing that both intracellular and intrahepatic reserves were
compromised. Plasma GSSG arises from both hepatic and
extrahepatic sites, and provides a sensitive index of whole-
body oxidant stress. However, as no increase in the plasma
GSSG/GSH ratio was observed, it must be assumed that the
glutathione redox cycle is still working efficiently and that
GSSG is being recycled to GSH by NADPH/glutathione
reductase. In our experience, high GSSG/GSH ratios only
occur in cirrhotic patients with severe disruption of hepatic
metabolism [Pemberton, unpublished results]. Vitamins A
and E were significantly reduced in our AIH patients. It
could be anticipated that a loss of vitamin A storage
capacity might arise when hepatic stellate cells undergo
transformation into myofibroblasts. Water-soluble vitamin C
levels were unaffected in our AIH group and patients
therefore retain their capacity for regeneration of vitamin
E by the vitamin C pathway.
As AIH is rare (170 cases per million in Northern Europe
[40]), it is difficult to recruit, in one centre, large numbers of
treatment-naı¨ve patients and this study therefore also
recruited patients receiving immunosuppressive treatment.
A few parameters differed significantly between treated and
untreated groups (whole serum antioxidant levels, serum
alkaline phosphatase and PIIINP) but some parameters
exhibited a wide range of values in both groups (such as
bilirubin and the transaminases) giving rise to significantoverlap and reflecting the diversity in disease activity found
in both treated and untreated groups. It is hoped that a future
study will use these markers of oxidative stress to monitor
the effect of treatment on naı¨ve patients over a prolonged
time period.
Our hypothesis that oxidative stress provides a link
between necroinflammation and fibrogenesis is strongly
supported by the results of this study which shows a
significant correlation between multiple markers of oxidant
stress and histologically assessed liver damage. The lipid
peroxidation marker 8-isoprostane correlated strongly with
total necroinflammatory score and, more significantly, with
the degree of interface hepatitis. Both 8-isoprostane and
total necroinflammatory score also correlated with serum
markers of hepatic injury and with PIIINP, a marker of
hepatic fibrogenesis, although not with hepatic fibrosis.
Although this finding does not necessarily imply a cause
and effect relationship, it strongly suggests that in type I
AIH, a link exists between oxidant stress and the activity of
the disease process leading to fibrogenesis. In addition to
oxidant stress, cytokines, mediators released by mononu-
clear cells, are likely to play a pathogenic role in AIH, a
condition characterised by a dense mononuclear cell infil-
trate and by altered levels of circulating cytokines [41,42].
Poli and Parola [43] suggested pathogenic mechanisms that
may link ROS generation, onset of lipid peroxidation, and
increased deposition of collagen and extracellular matrix: he
observed that, as lipid peroxidation-derived aldehydes che-
moattract and activate inflammatory cells and oxidant stress
is known to modulate the expression of genes encoding for
inflammatory cytokines, oxidant stress will trigger an in-
crease in inflammatory activity; second, lipid peroxidation is
known to up-regulate the expression and synthesis of
fibrogenic cytokines, whilst aldehydic end products of lipid
peroxidation enhance type I collagen synthesis by fibro-
blasts and HSC. It has been proposed [44] that progression
to fibrosis is primarily governed by the steady-state con-
centration of oxidant stress-related molecules, i.e. oxidative
stress appears to be causally related to an increase in
fibrogenesis and suitable antioxidant supplementation may
prevent it. Although a significant correlation was found
between urinary 8-isoprostane and PIIINP, a marker of
hepatic fibrogenic activity, no correlation was found be-
tween markers of oxidant stress and histologically assessed
fibrosis in our study. This is likely to be a result of the low
fibrotic score observed in almost all the AIH patients
biopsied and emphasises that the observed oxidative stress
is likely to be a consequence of early disease processes
rather than just a feature of late stage decompensated liver
disease.
In conclusion, our study shows that oxidant stress,
assessed for the first time in a large group of AIH patients
using a wide range of markers of both oxidant and antiox-
idant processes in blood and urine, is not just a feature of
late stage decompensated liver disease but is a significant
feature of early AIH. We have also shown, in this group of
P.W. Pemberton et al. / Biochimica et Biophysica Acta 1689 (2004) 182–189188patients with early stage AIH, a clear association between
markers of oxidant stress and histologically assessed in-
flammation and hepatic fibrogenesis. Trials of antioxidant
therapy, adequately monitored, are therefore now indicated,
especially in patients who fail to respond to prednisone and
azathioprine treatment, to determine whether such treatment
can prevent or slow progression to cirrhosis and liver
failure.Acknowledgements
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